摘要
目的：观察胸腔置管引流并顺铂（DDP）、白介素-2（IL-2）局部灌注联合多西紫杉醇（DXL）静脉化疗治疗非小细胞肺癌（ NSCLC）胸腔积液的临床疗效。方法将入选的113例NSCLC胸腔积液患者随机分为观察组（59例）、对照组（54例），两组均予胸腔置管引流，对照组予DDP胸腔灌注并DXL静脉化疗，观察组予DDP＋IL-2胸腔灌注并DXL静脉化疗，灌注3-4次，静脉化疗2个周期，对比两组用药毒性反应、肿瘤标志物水平与疗效构成。结果治疗结束后1个月，两组胸腔积液总体疗效构成未见显著性差异（ P〉0．05）；观察组总体有效率（89．8%）、临床获益率（98．3%）均高于对照组（79．6%、92．6%）（P〉0．05）。观察组治疗后CEA、CA125、CYFRA21-1均显著低于对照组（P〈0．05）。两组药物毒性反应发生率差异无统计学意义（P〉0．05）。结论 DDP胸腔灌注联合DXL静脉化疗治疗 NSCLC引发的胸腔积液基础上，联合IL-2灌注，可在不增加药物毒性反应前提下进一步提高临床疗效。
Objective To observe the clinical efficacy and safety of cisplatin and IL-2 thoracic cavity perfusion combined with DXL chemotherapy in the treatment of non-small cell lung cancer patients with pleural effusion. Methods 103 NSCLC patients with pleural effusion were selected and randomly divided into the observation group （59 cases） and the control group （54 cases）. All patients were given thoracic cavity catheter drainage guided by B ultrasound, then the control group was given DDP intrapleural perfusion and DXL intravenous chemotherapy, and the observation group was given DDP ＋ IL-2 intrapleural perfusion and DXL intravenous chemotherapy. They were perfused for 3-4 times, and were given 2 cycles of intravenous chemotherapy. Their drug toxicities and clinical efficacy were compared between the two groups. Results 1 months after the treatment, the clinical efficacy on pleural effusion showed no significant difference between the two groups （Z=1. 426, P=0. 154）. The overall effective ratio was 89. 8% and the clinical benefit ratio was 98. 3% in the observation group, which were higher than those of the control group （79. 6% and 92. 6%） （P〉0. 05）. The levels of CEA, CA125 and CYFRA21-1 were significantly lower in the observation group than in the control group （P〈0. 05）. There was no significant difference in the incidence of adverse reactions between the two groups （ P 〉0. 05 ） . Conclusion Based on thoracic cavity catheter drainage and DDP perfusion combined with DXL intravenous chemotherapy, IL-2 perfusion can further improve clinical efficacy and without any increase of drug toxicity in the treatment of NSCLC patients with pleural effusion.
出处
《临床肺科杂志》
2015年第12期2144-2148,共5页
Journal of Clinical Pulmonary Medicine
